Quantcast

Latest fibrosis Stories

2014-06-25 12:30:48

MENLO PARK, Calif., June 25, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014. Mr. Welch has more than 20 years of experience in financial and operational management at life science and high technology firms....

2014-06-10 12:30:38

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Fibrosis - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/treatments/fibrosis_pipeline_review_h1_2013.html Fibrosis - Pipeline Review, H1 2014SummaryGlobal Markets Direct's, 'Fibrosis - Pipeline Review, H1 2014', provides an overview of the Fibrosis's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Fibrosis, complete...

2014-06-10 12:30:16

CHICAGO, June 10, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013. "Our partnership with Biogen Idec will further enhance the PFF Patient Registry, allowing us to investigate fundamentally important questions in...

2014-06-04 08:26:06

Renowned health writer documents discovery of modified citrus pectin in her latest book SANTA ROSA, Calif., June 4, 2014 /PRNewswire/ -- One of the nation's leading writers on the use of naturopathic medicine has released a new book documenting groundbreaking studies on modified citrus pectin (MCP) and its application for addressing serious health issues like cancer, heart disease, chronic inflammation and fibrosis. The book, New Twist on Health: Modified Citrus Pectin for Cancer,...

2014-05-18 16:20:49

Results from Boehringer Ingelheim, InterMune and IPFnet clinical trials discussed CHICAGO, May 18, 2014 /PRNewswire-USNewswire/ -- WHO: The Pulmonary Fibrosis Foundation (PFF) will discuss results from recent idiopathic pulmonary fibrosis (IPF) clinical trials in an upcoming webinar. Boehringer Ingelheim and InterMune both recently released data from their Phase III randomized, placebo-controlled trials, each demonstrating efficacy for those living with IPF. Also results from the...

2014-05-16 08:24:21

Now includes information about InterMune's Expanded Access Program CHICAGO, May 16, 2014 /PRNewswire/ -- The newly launched Pulmonary Fibrosis Foundation Patient Communication Center (PCC) has become the destination for the most up-to-date information for the pulmonary fibrosis community. The PCC now has information about the Expanded Access Program (EAP) for pirfenidone. "The Pulmonary Fibrosis Foundation (PFF) is committed to serve as an impartial resource for the PF community,"...

2014-04-28 10:15:29

Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation may also be crucial to the healing and repair processes in the lungs.  Elizabeth Redente, PhD, assistant professor of cell biology at National Jewish Health, and her colleagues report in the April 2014 issue of the American Journal of Respiratory Cell and Molecular...

2014-04-18 13:49:48

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma. Fibrosis, or scarring, is a hallmark of the disease, and progressive tightening of the skin and lungs can lead to serious organ damage and, in some cases, death. The concept for new therapeutic options centers on findings made by Swati Bhattacharyya, PhD, research assistant professor in Medicine-Rheumatology, who identified the role...

2014-03-27 12:30:22

CHICAGO, March 27, 2014 /PRNewswire-USNewswire/ -- Patients with pulmonary fibrosis (PF), their caregivers, family members, and health care providers will now be able to access a centralized communications center. Established by the Pulmonary Fibrosis Foundation (PFF), the leading pulmonary fibrosis patient advocacy organization, the PFF Patient Communication Center (PCC) will be the first-ever comprehensive communication resource that will be available to the PF community. This...

2014-03-20 12:29:25

LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Liver Fibrosis Global Clinical Trials Review, H2, 2013 Liver Fibrosis Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Liver Fibrosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.